Manufacturers

Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?

Manufacturers

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

HTA Quarterly | Fall 2023

Manufacturers

Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties

Manufacturers

The cures conundrum: The importance of getting value assessment right for transformational therapies

Manufacturers

VPAS—Where next?

Manufacturers

Empower your people and brand with biopharma learning solutions

Manufacturers

On-demand webinar: The EU JCA process: Opportunities and challenges in bringing innovative medicines to patients in Europe

Reimbursement considerations for home infusions

Copay accumulator adjustment programs significantly increase patient financial burden

Issue Brief: Assessing the impact of formulary exclusion on healthcare costs and outcomes for patients on therapy for certain chronic conditions

Manufacturers

Recap Asembia 2023: Our impactful contributions to the premier specialty pharmacy conference

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?